Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia
Details : IMC-001 is a PD-L1 antibody, an immune checkpoint inhibitor. This antibody activates the anticancer functions of T cells by strongly inhibiting the binding between PD-1 expressed on T cells and PD-L1 expressed on the surface of cancer cells.
Product Name : IMC-001
Product Type : Antibody
Upfront Cash : Inapplicable
May 12, 2022
Details : The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China (Mainland China, Hong Kong, Macau, and Taiwan).
Product Name : IMC-002
Product Type : Antibody
Upfront Cash : $8.0 million
March 31, 2021
Reset All
